The single idea underneath Adam O’Dell’s “Imperium” pitch is that biology is becoming a software discipline. Call it synthetic biology, engineering biology, or simply writing DNA, the premise is the same: if living things run on code, then the companies that can read, write, and run that code are positioned the way chip and software companies were positioned in the 1980s. This explainer walks through what the field actually is, how the read-write-program layering works, and why it is the engine behind the entire Imperium thesis.
What Is Synthetic Biology?
Synthetic biology is the practice of engineering living systems. Where traditional biology studies how organisms work, synthetic biology treats organisms and their DNA as systems to be designed and built. A researcher no longer has to wait for nature to produce a useful molecule; they can specify the genetic instructions for it, have those instructions printed as physical DNA, and insert them into a cell that then manufactures the molecule on demand.
That is why the software analogy is so persistent, and why the Imperium pitch leans on it so hard. The field borrows the vocabulary of computing deliberately: genes as code, cells as machines, and DNA synthesis as the compiler that turns a written sequence into something a cell can run. It is a simplification, but a useful one, because it turns a dizzyingly complex field into a story about a technology getting faster and cheaper the way computing did.
DNA as Software: The Read, Design, Write Stack
The cleanest way to understand the field is as a three-step loop. First you read DNA, decoding the sequence of a genome or a gene. Then you design, choosing the specific sequence you want to build, often with software and increasingly with AI. Then you write, synthesizing that sequence as real, physical DNA you can put to work.
The pitch’s central quote captures this in one sentence: “Once you can read, design, and write the code of living things, every industry that sells an animal, a plant, a fiber, or a molecule is suddenly just a software problem.”
Each step of the loop has a dedicated industry behind it. Sequencing companies handle the read step. Synthesis companies handle the write step. The design step, once the slowest and most manual, is where AI has begun to accelerate everything, and it is why the field keeps getting described in computing terms.
The Three-Layer Stack in the Imperium Pitch
O’Dell maps the computing era onto the field with a three-layer stack. Twist Bioscience is the silicon layer, the “Intel” of the DNA revolution, making the physical DNA on silicon chips. Ginkgo Bioworks is the software layer, the “Microsoft,” positioned as the operating system that runs on top of that silicon. Absci is the apps layer, the layer that produces end products, with a baldness drug called ABS-201 as its headline application.
It is a tidy analogy, and it borrows directly from a real quote out of Twist’s own chief executive, who once said of the two companies, “We’re Intel, they’re Microsoft.” The history of computing really did sort into those layers, and the pitch is betting that biology will sort the same way. Whether that bet pays off is a separate question from whether the analogy is helpful, and it is undeniably helpful as a teaching frame. You can read more about the two anchor names in our Twist Bioscience stock piece and our Ginkgo Bioworks stock piece.
The Scale Claims, and the Reality
The pitch reaches for big numbers to make the field feel total. It cites McKinsey in arguing that synthetic biology could “disrupt 60% of the physical inputs in the global economy” across industries worth something like $65 trillion. Those are directional claims about a real, well-funded field, and they should be read as upper-bound framing rather than precise forecasts.
The more modest reality is still notable. Real money has already flowed into the space. Illumina, Thermo Fisher, and Danaher compete at the equipment layer, and a long list of serious buyers and funders, including DARPA, ARPA-H, the NSF, Amazon, Eli Lilly, and Anthropic, have put capital behind DNA synthesis and DNA-driven drug discovery. Amazon even set up a program to design DNA applications and selected Twist as its silicon layer and Ginkgo as its software layer. That is the kind of quiet validation that sits underneath the louder headline numbers.
Why Investors Are Watching
The reason the field keeps surfacing in investment pitches is the same reason computing dominated the last fifty years of markets: a technology that gets cheaper on a predictable curve tends to pull enormous value toward the companies that own the curve. Synthetic biology is earlier in that journey than semiconductors were in 1980, and the individual names carry biotech-level volatility, which is a polite way of saying they can be cut in half.
For investors, the useful takeaway is to separate the theme from the specific tickers. The theme is real and well funded. The specific picks, and the specific prices at which they trade, are a different matter, and the write step of the stack is where the economics get most interesting. For a closer look at how synthetic DNA actually gets written, see our DNA synthesis explainer.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.